How Alzheimer's mutates the immune system

nature video
11 followers
Sep 26, 2024
David Gate studies how neurodegenerative disease changes the immune system
And for people with Alzheimer's disease, some of the changes he and his colleagues have identified are at the genetic level - with one modification to T cells potentially leading to an abnormal inflammatory response in the brain. Now he thinks that understanding and targeting these changes could be a route to treating the disease.
Read more about Alzheimer's disease https://www.nature.com/collections/adgggicdca
This Nature Video is editorially independent. It is produced with third party financial support. Read more about Supported Content here: https://partnerships.nature.com/commercial-content-at-nature-research/
We're in a new frontier of Alzheimer's disease research. Historically we've been relegated to
analysing a few proteins to look at the pathology of Alzheimer's disease, but now we can look at
that pathology in conjunction with all of the genomic changes surrounding that pathology.
David Gate studies how neurodegenerative disease changes the immune system,
and for Alzheimer's patients, some of these changes are at the genetic level.
And it alters the ability of the immune system to respond to pathogens, to initiate inflammatory
responses. Now he thinks that understanding and targeting these changes could be a route
to treating the disease. Well I'd always been interested in the immune system and the communication
between the brain and the immune system. During my training I noticed that a lot of the newer
genomics tools that were coming onto the theme had not yet been applied to Alzheimer's and
especially the Alzheimer's disease immune system. So that's where I started with Tony Weiss-Garay
at Stanford University. We discovered that the cerebral spinal fluid, this is a fluid that flows
in your spinal column and in and around your brain, is transcriptionally altered. That means that the
genes of your cerebral spinal fluid immune cells change with Alzheimer's disease. This was a rather
striking finding to us. There was at the time very little known about the cerebral spinal fluid
immune system. And we followed this up to study other neurodegenerative diseases with different
underlying causes. These diseases are known as Lewy body dementias. And we found that the cerebral
spinal fluid immune system is also altered in those patients, but it's altered in a different
way. And so this was a very intriguing result to us, which suggested that these different brain
diseases, which have different underlying causes, both have immune system changes in the cerebral
spinal fluid. And this raises the tantalizing possibility that perhaps we can treat these
diseases by mitigating this inflammatory response that we see in the cerebral spinal fluid.
This is perhaps a way of modulating the neuroinflammation of Alzheimer's disease that,
as we now all know, is the prime component of this disorder. More recently, David has set up his own
lab, where he continues to investigate the links between neurodegenerative disease and the immune
So we're able to analyze the genetic content of single cells and look at the changes that occur
among immune cell populations. So in this study, we found that there is an epigenetic modification
to a gene called CXCR3. And you can think of this gene as a sort of antenna on the surface of cells
that allows them to traffic into the brain. David's findings suggest that this change
increases expression of CXCR3 on T-cells, which could encourage more of these cells into the brain
where they might contribute to the abnormal inflammatory response observed in the brains of
people with Alzheimer's disease. And so this might be a target that we can therapeutically modulate
to treat Alzheimer's disease. This research also stratified patients based on which APOE gene they
have. APOE is a gene involved in the metabolism of fats and comes in three main subtypes,
with APOE4 being linked to an increased risk of Alzheimer's disease. We discovered that APOE4
carriers have a more inflamed immune system. And we identified the genes that mediate that
inflamed immune system in these patients. The immune system of Alzheimer's disease patients
is altered at the genetic level. So we believe that targeting the immune system, that reversing
these epigenetic changes, or reprogramming these cells that we think are bad into cells that we
think could be good for the disease, would be a smart therapeutic strategy to treat Alzheimer's
disease. Next though, David thinks researchers may need to better understand some of the therapies
that are already being administered. So what I'm most interested now is in these new therapeutic
drugs for Alzheimer's disease, these anti-amyloid monoclonal antibodies. These are now administered
to patients, but we know very little about how they might alter the immune system of these
patients, and how that alteration of the immune system might lead to better or worse disease
outcomes for these drugs.
